Table 4. Hepcidin, EPO and α-Klotho Changes During the Evaluation Period.
| ESA type | Month 3 | Month 6 | P |
|---|---|---|---|
| Hepcidin, pg/mL | |||
| EB | 995 (244 - 1,308) | 1,103 (161 - 1,345) | 0.95 |
| CERA | 1,094 (234 - 1,390) | 215 (157 - 922) | 0.02 |
| EPO, mIU/mL | |||
| EB | 7.7 (4.1 - 11.6) | 12.1 (4.1 - 22.4) | 0.09 |
| CERA | 13.3 (10.8 - 17.1)* | 22.6 (14.5 - 41.9)* | 0.08 |
| α-Klotho, pg/mL | |||
| EB | 514 (417 - 584) | 493 (370 - 526) | 0.01 |
| CERA | 540 (455 - 741) | 409 (360 - 534) | 0.03 |
Data are presented as median (P25 - P75). *P < 0.05 respect to EB. α-Klotho: soluble α-Klotho; CERA: continuous erythropoietin receptor activator; EB: epoetin-β; EPO: erythropoietin; ESA: erythropoietin-stimulating agent.